Tuesday, November 17, 2026
RSS


← All Stories

Pharmaceutical

Bristol Myers Squibb Gains on Dual Phase 3 Wins and CAMZYOS Label Expansion

Bristol Myers Squibb shares gained on dual Phase 3 wins, CAMZYOS expansion and fresh analyst commentary on its IPF pipeline.

Oct 13, 2026
Pharmaceutical

Bristol Myers Squibb Stock Jumps 6.5% on Dual Phase 3 Wins and Expanded CAMZYOS Approval

Bristol Myers Squibb shares jumped 6.5% after two positive Phase 3 updates and expanded FDA approval for CAMZYOS strengthened its clinical s…

Oct 13, 2026
Pharmaceutical

Syndax Stock Drops 12.2% After Axatilimab Trial Miss Raises Biotech Risk Concerns

Syndax shares fell 12.2% to $14.54 in pre-open trading after its MAXPIRe Phase 2 axatilimab trial did not meet expectations.

Oct 13, 2026
Pharmaceutical

UnitedHealth Raises 2026 Profit Outlook as Q3 Beat Overcomes Medical-Cost Pressure

UnitedHealth topped Q3 estimates and raised its 2026 profit outlook, offering a closely watched signal for managed care and healthcare spend…

Oct 13, 2026
Pharmaceutical

STERIS to Buy Xodus Medical for $2.1 Billion in Surgical-Device Expansion

STERIS’s $2.1 billion purchase of Xodus Medical would broaden its surgical-device portfolio and underscore healthcare’s continuing consolida…

Oct 12, 2026
Pharmaceutical

Solventum Seeks Offers for Health Information Systems Business in Potential Divestiture

Solventum is reportedly collecting offers for its Health Information Systems business, signaling a possible portfolio review without confirm…

Oct 12, 2026
Pharmaceutical

Bristol Myers Squibb Jumps 6.5% After Twin Phase 3 Trial Wins

Bristol Myers Squibb rose 6.5% after two positive Phase 3 readouts, but mixed insider and guru positioning adds a note of caution.

Oct 12, 2026
Pharmaceutical

Vaxcyte Stock Surges After $1.15 Billion Raise for VAX-31 Vaccine Program

Vaxcyte’s $1.15 billion public offering strengthens its balance sheet, supports VAX-31 development and reduces near-term financing risk.

Oct 12, 2026
Pharmaceutical

STERIS’s $2.1 Billion Xodus Medical Deal Tests Healthcare M&A Appetite

STERIS’s $2.1 billion Xodus Medical agreement puts financing, dilution and medical-device M&A appetite under the microscope.

Oct 12, 2026
Pharmaceutical

Bristol Myers Squibb Stock Jumps on Rare Double Phase 3 Success

BMY shares rose 5.7% to 6.5% after two positive Phase 3 readouts, putting pipeline value and analyst targets back in focus.

Oct 12, 2026
Pharmaceutical

Lipocine’s TLANDO Approval Opens a New Canadian Test for $LPCN

Health Canada’s approval of TLANDO gives Lipocine a Canadian commercial pathway, with Verity Pharma targeting a launch by the end of 2026.

Oct 11, 2026
Pharmaceutical

Merck and Moderna’s Positive Phase 3 Cancer Vaccine Data Reshape the Oncology Trade

Merck’s Keytruda gains and Moderna’s 9% stock pop highlight two distinct oncology narratives: established scale and potential mRNA growth.

Oct 11, 2026